Sino Biopharmaceutical (HKG:1177) presented preliminary data from its first-in-human Phase I clinical study of cancer drug TQB2102 at the 2025 ASCO Annual Meeting, according to a Tuesday filing with the Hong Kong Exchange.
The company reported encouraging results, with response rates of up to 70% in certain HER2-positive cancers, including breast and gastric cancers -- even among patients who had not responded to prior treatments.
Side effects were described as manageable, with only a few cases of serious lung-related adverse events.
TQB2102 is currently in Phase 3 trials and, if successful, could become the world's first approved bispecific HER2 antibody-drug conjugate (ADC), the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.